Bone metabolism assessment in diabetes mellitus type 1

Abstract

Aim. To evaluate the effect of changes occuring in the organism in diabetes mellitus type 1 on the state of bone mineral density and its metabolism parameters; to determine the changes in serum markers of bone remodeling and bone mineral density in this disease.

Methods. Bone mineral density (by dual-energy X-ray absorptiometry) and serum markers of bone remodeling (total alkaline phosphatase activity, level of aminoterminal propeptide of type 1 procollagen and C-terminal telopeptide) were examined in 98 patients with diabetes mellitus type 1 and in the control group consisting of 82 subjects.

Results. The average concentration of C-terminal telopeptide in the blood serum of patients with type 1 diabetes (0.525±0.03 ng/ml) was significantly higher in comparison to the control group (0.424±0.02 ng/ml; p <0.01). Proximal femoral T-score in type 1 diabetes was significantly lower than the average value in the control group: -1.44±0.15 and -0.49±0.17 (p <0.001). In the femoral neck it was -1.68±0.14 and -0.64±0.18 (p <0.001), in LI-IV zone -2.04±0.16 and -0.73±0.19, respectively (p <0.001). Moderate negative significant correlation was found between T-score (LI-IV) and level of C-terminal telopeptide (r=-0.431, p=0.000).

Conclusion. In patients with diabetes mellitus osteopenia is a relatively frequent complication, but bone loss increases with duration and decompensation of the disease; evaluation of bone mineral density and C-terminal telopeptide level (bone resorption marker) promotes detection of bone metabolism abnormalities at any stage of the disease, especially in the long-term course of type 1 diabetes.

Keywords

diabetes mellitus type 1 / bone mineral density / osteoporosis

References

[1] Johnston S., Conner C., Aagren M. et al. Association between hypoglycaemic events and fall-related fractures in medicare-covered patients with type 2 diabetes. Diabetes Obes. Metab. 2012; 14 (7): 634–643. DOI: 10.1111/j.1463-1326.2012.01583.x.

[2] Johnston S., Conner C., Aagren M. et al. Association between hypoglycaemic events and fall-related fractures in medicare-covered patients with type 2 diabetes. Diabetes Obes. Metab. 2012; 14 (7): 634-643. DOI: 10.1111/j.1463-1326.2012.01583.x.

[3] Compston J. Osteoporosis: social and economic impact. Radiol. Clin. N. Am. 2010; 48 (3): 477–482. DOI: 10.1016/j.rcl.2010.02.010.

[4] Compston J. Osteoporosis: social and economic impact. Radiol. Clin. N. Am. 2010; 48 (3): 477-482. DOI: 10.1016/j.rcl.2010.02.010.

[5] Coe L.M., Irwin R., Lippner D., McCabe L.R. The bone marrow microenvironment contributes to type I diabetes in duced osteoblast death. J. Cell Physiol. 2011; 226: 477–483. DOI: 10.1002/jcp.22357.

[6] Coe L.M., Irwin R., Lippner D., McCabe L.R. The bone marrow microenvironment contributes to type I diabetes in duced osteoblast death. J. Cell Physiol. 2011; 226: 477-483. DOI: 10.1002/jcp.22357.

[7] Starup-Linde J., Vestergaard P. Biochemical bone turnover markers in diabetes mellitus — a systematic review. Bone. 2016; 82: 69–78. DOI: 10.1016/j.bone.2015.02.019.

[8] Starup-Linde J., Vestergaard P. Biochemical bone turnover markers in diabetes mellitus - a systematic review. Bone. 2016; 82: 69-78. DOI: 10.1016/j.bone.2015.02.019.

[9] Ghodsi M., larijani B., Keshtkar A. et al. Mechanisms involved in altered bone metabolism in diabetes: a narrative review. J. Diabetes Metab. Disord. 2016; 15: 52. DOI: 10.1186/s40200-016-0275-1.

[10] Khvisyuk A.N., Sykal A.A., Babalyan A.V. et al. Assessment of fracture risk in patients with diabetes. Ortopediya, travmatologiya i protezirovanie. 2015; 2: 35–41. (In Russ.)

[11] Хвисюк A.Н., Сыкал A.А., Бабалян А.В. и др. Оценка риска перелома у пациентов с сахарным диабетом. Ортопедия, травматол. и протезирование. 2015; 2: 35-41. DOI: 10.15674/0030-59872015235-41.

[12] Lewiecki E.M., Gordon C.M., Baim S. et al. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone. 2008; 43 (6): 1115–1121. DOI: 10.1016/j.bone.2008.08.106.

[13] Lewiecki E.M., Gordon C.M., Baim S. et al. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone. 2008; 43 (6): 1115-1121. DOI: 10.1016/j.bone.2008.08.106.

[14] Lederer E. Regulation of serum phosphat. J. Physiol. 2014; 592 (Pt. 18): 3985–3995. DOI: 10.1113/jphysiol.2014.273979.

[15] Lederer E. Regulation of serum phosphat. J. Physiol. 2014; 592 (Pt. 18): 3985-3995. DOI: 10.1113/jphysiol.2014.273979.

[16] Zhang D., Maalouf N.M., Adams-Huet B. et al. Effects of sex and postmenopausal estrogen use on serum phosphorus levels: a cross-sectional study of the National Health and Nutrition Examination Survey (NHANES) 2003–2006. Am. J. Kidney Dis. 2014; 63: 198–205. DOI: 10.1053/j.ajkd.2013.07.012.

[17] Zhang D., Maalouf N.M., Adams-Huet B. et al. Effects of sex and postmenopausal estrogen use on serum phosphorus levels: a cross-sectional study of the National Health and Nutrition Examination Survey (NHANES) 2003-2006. Am. J. Kidney Dis. 2014; 63: 198-205. DOI: 10.1053/j.ajkd.2013.07.012.

[18] Nowicki M., Fliser D., Fode P., Ritz E. Changes in plasma phosphate levels influence insulin sensitivity under euglycemic conditions. J. Clin. Endocrinol. Metab. 1996; 81:156–159. DOI: 10.1210/jcem.81.1.8550745.

[19] Nowicki M., Fliser D., Fode P., Ritz E. Changes in plasma phosphate levels influence insulin sensitivity under euglycemic conditions. J. Clin. Endocrinol. Metab. 1996; 81:156-159. DOI: 10.1210/jcem.81.1.8550745.

[20] Khattab M., Abi-Rashed C., Ghattas H. et al. Phosphorus ingestion improves oral glucose tolerance of healthy male subjects: a crossover experiment. Nutrition J. 2015; 14: 112. DOI: 10.1186/s12937-015-0101-5.

[21] Liamis G., Liberopoulos E., Barkas F., Elisaf M. Diabetes mellitus and electrolyte disorders. World J. Clin. Cases. 2014; 2 (10): 488–496. DOI: 10.12998/wjcc.v2.i10.488.

[22] Liamis G., Liberopoulos E., Barkas F., Elisaf M. Diabetes mellitus and electrolyte disorders. World J. Clin. Cases. 2014; 2 (10): 488-496. DOI: 10.12998/wjcc.v2.i10.488.

[23] Teegarden D., Donkin S. Vitamin D: emerging new roles in insulin sensitivity. Nutrition Res. Rev. 2009; 22 (1): 82–92. DOI: 10.1017/S0954422409389301.

[24] Teegarden D., Donkin S. Vitamin D: emerging new roles in insulin sensitivity. Nutrition Res. Rev. 2009; 22 (1): 82-92. DOI: 10.1017/S0954422409389301.

[25] Ivarsson K.M., Clyne N., Almquist M., Akaberi S. Hyperparathyroidism and new onset diabetes after renal transplantation. Transplant. Proc. 2014; 46: 145–150. DOI: 10.1016/j.transproceed.2013.07.076.

[26] Ivarsson K.M., Clyne N., Almquist M., Akaberi S. Hyperparathyroidism and new onset diabetes after renal transplantation. Transplant. Proc. 2014; 46: 145-150. DOI: 10.1016/j.transproceed.2013.07.076.

RIGHTS & PERMISSIONS

Safarova S.S.